Actinium Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; filed May 15, 2023. The unaudited statements include normal recurring adjustments. Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies; it reported no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Total revenue | $0 | $0.94 million |
| Research and development expense, net | $7.85 million | $4.37 million |
| General and administrative expense | $3.74 million | $1.74 million |
| Operating loss | $11.58 million | $5.16 million |
| Interest income | $0.55 million | $0.04 million |
| Net loss; loss per share | $11.04 million; $0.43 | $5.13 million; $0.23 |
| Operating cash used | $15.08 million | $5.78 million |
Revenue was nil in Q1 2023; the prior-year $0.94 million comprised collaboration and grant revenue, neither of which recurred in the quarter. No profit margin is meaningful given the absence of revenue and continuing losses.
Cash and cash equivalents were $94.52 million at March 31, 2023, down from $108.91 million at year-end 2022; total cash, cash equivalents and restricted cash were $95.23 million. Current assets were $98.55 million and current liabilities $7.86 million. Total liabilities were $44.82 million, including $35.0 million of deferred Immedica license revenue and lease obligations; the filing reports no borrowings. Stockholders’ equity was $57.21 million.
Q1 operating cash use increased by $9.30 million year over year, reflecting the higher net loss, lower accounts payable and accrued expenses, and increased prepaid expenses. The company raised $0.77 million net through share sales in the quarter. After quarter-end, it sold 0.6 million shares for $5.6 million net proceeds. The company stated that existing resources were expected to fund planned operations for more than 12 months after filing; elsewhere it estimated runway through 2025. These are management expectations, not assurance of funding through that date.
Material developments and outlook
- Iomab-B: Management reported that the Phase 3 SIERRA trial met its primary endpoint of durable complete remission at 180 days (p<0.0001). The filing describes substantial transplant access and favorable exploratory survival comparisons. However, the secondary overall-survival endpoint was not met in the intent-to-treat analysis, which management said was confounded by crossover. Investors should distinguish this result from the exploratory comparisons.
- The company planned to complete and submit an Iomab-B U.S. BLA in the second half of 2023, with potential U.S. commercialization in 2024 if approved. It was also working toward an early access program. Immedica holds EUMENA rights; the $35 million upfront payment remains deferred and is expected to be recognized upon EU regulatory approval. The company expected an EU marketing application in 2024.
- Actimab-A: The company reported early combination-trial findings, including 1- and 2-year survival of 53% and 32% with CLAG-M, and described plans for late-stage development under its February 2023 NCI collaboration. These clinical findings are not evidence of regulatory approval or established efficacy.
- Spending: R&D expense rose primarily due to manufacturing and chemistry, manufacturing and controls work for the planned Iomab-B BLA and higher compensation. Management expected some BLA-related CMC spending in the first half of 2023 to be one-time, with lower CMC expense anticipated in the second half. G&A increased with professional, consulting and legal fees, compensation, and equity compensation.
Risks, contingencies and unusual items
- The company has no approved products or commercial sales, has recurring losses, and depends on financing, clinical progress and regulatory decisions. Future equity issuance may dilute shareholders.
- Key risks include FDA review and potential requests for further data, clinical and safety outcomes, reimbursement and market adoption, reliance on third-party manufacturers and isotope suppliers, and the ability to establish commercial and supply-chain capabilities.
- Actinium disclosed an arbitration and related dispute with a former employee involving alleged confidentiality and non-compete violations. A permanent injunction was granted April 25, 2023; the filing says the restriction on certain competing work runs through April 1, 2024. This matter was discussed in risk factors despite “None” being reported under the Legal Proceedings item.
- Management said disclosure controls were effective as of March 31, 2023 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Regulatory status, filing timing and FDA feedback for the planned Iomab-B BLA; verify that the SIERRA data support the intended application and indication.
- Final and fully reviewed SIERRA results, especially the distinction between the unmet ITT overall-survival endpoint and favorable exploratory analyses.
- Cash burn, actual runway, subsequent equity proceeds and potential dilution; reconcile the stated runway through 2025 with the more-than-12-month liquidity statement.
- Timing and costs of BLA-enabling manufacturing work, and availability and qualification of third-party manufacturing and isotope supplies.
- Progress of Actimab-A and Iomab-ACT studies, and the terms, milestones and revenue recognition conditions under the Immedica license.